Deubiquitinating enzyme inhibitors and their potential in cancer therapy

Current Cancer Drug Targets

Volumn 14, Issue 6, 2014, Pages 506-516

  Crosas, Bernat ^a  

^a INSTITUT DE BIOLOGIA MOLECULAR DE BARCELONA   (Spain)

Author keywords

Deubiquitinating enzymes; DUBs; Inhibitors; Proteasome; Small molecule; Ubiquitin specific proteases; USP1; USP14; USP7; USP8; USP9x

Indexed keywords

BORTEZOMIB; CHALCONE DERIVATIVE; DEUBIQUITINASE; DEUBIQUITINASE INHIBITOR; PROTEIN INHIBITOR; PROTEIN P53; UAF1 INHIBITOR; UBIQUITIN CONJUGATING ENZYME E2; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG; USP1 INHIBITOR; USP11 INHIBITOR; USP7 INHIBITOR; USP8 INHIBITOR; VIALININ A; 19S PROTEIN; AURANOFIN; CARFILZOMIB; DEUBIQUITINATING ENZYME INHIBITOR; ENZYME INHIBITOR; FANCONI ANEMIA PROTEIN; UBIQUITIN; USP1 UAF1 INHIBITOR; USP14 PROTEIN; USP7 DEUBIQUITINATING ENZYME INHIBITOR; ANTINEOPLASTIC AGENT; PROTEASOME; PROTEASOME INHIBITOR;

APOPTOSIS; ARTICLE; CANCER THERAPY; DNA DAMAGE; ENZYME ACTIVE SITE; ENZYME ACTIVITY; HUMAN; NERVE DEGENERATION; NONHUMAN; RECEPTOR DOWN REGULATION; SEVERE ACUTE RESPIRATORY SYNDROME; SIGNAL TRANSDUCTION; UBIQUITINATION; BIOLOGICAL ACTIVITY; CELL DEATH; ENZYME INHIBITION; GENETIC TRANSCRIPTION; HOMEOSTASIS; HUMAN GENOME; MULTIPLE MYELOMA; PROTEIN DEGRADATION; PROTEIN STABILITY; PROTEIN SYNTHESIS REGULATION; TUMOR CELL; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG DESIGN; DRUG EFFECTS; ENZYMOLOGY; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DESIGN; HUMANS; MOLECULAR TARGETED THERAPY; MULTIPLE MYELOMA; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEASOME INHIBITORS; PROTEOLYSIS; SIGNAL TRANSDUCTION; UBIQUITIN-PROTEIN LIGASE COMPLEXES; UBIQUITIN-PROTEIN LIGASES; UBIQUITIN-SPECIFIC PROTEASES; UBIQUITINATION;

EID: 84907328599     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/1568009614666140725090620     Document Type: Article

References (118)

1. el Alaoui, S.; Legastelois, S.; Roch, A.M.; Chantepie, J.; Quash, G. Transglutaminase activity and N epsilon (gamma glutamyl) lysine isopeptide levels during cell growth: an enzymic and immunological study. Int. J. Cancer, 1991, 48 (2), 221-226.
2. Zaabczyk, M.; Głowacki, R.; Machnik, A.; Herod, P.; Kazek, G.; Jakubowski, H.; Undas A. Elevated concentrations of Ne{open}homocysteinyl- lysine isopeptide in acute myocardial infarction: links with ADMA formation. Clin. Chem. Lab. Med., 2011, 49 (4), 729-735.
3. Finley, D. Recognition and processing of ubiquitin-protein conjugates by the proteasome. Annu. Rev. Biochem., 2009, 78, 477-513.
4. Hochstrasser, M. Origin and function of ubiquitin-like proteins. Nature, 2009, 458, 422-429.
5. Komander, D.; Rape, M. The ubiquitin code. Annu. Rev. Biochem., 2012, 81, 203-229.
6. Burroughs, A.M.; Iyer, L.M.; Aravind, L. Natural history of the E1- like superfamily: implication for adenylation, sulfur transfer, and ubiquitin conjugation. Proteins, 2009, 75, 895-910.
7. Orlicky, S.; Tang, X.; Willems, A.; Tyers, M.; Sicheri, F. Structural basis for phosphodependent substrate selection and orientation by the SCFCdc4 ubiquitin ligase. Cell, 2003, 112 (2), 243-256.
8. Ingham, R.J.; Gish, G.; Pawson, T. The Nedd4 family of E3 ubiquitin ligases: functional diversity within a common modular architecture. Oncogene, 2004, 23 (11), 1972-1984.
9. Choi, W.S.; Jeong, B.C.; Joo, Y.J.; Lee, M.R.; Kim, J.; Eck, M.J.; Song, H.K. Structural basis for the recognition of N-end rule substrates by the UBR box of ubiquitin ligases. Nat. Struct. Mol. Biol., 2010, 17 (10), 1175-1181.
10. Bazirgan, O.A.; Hampton, R.Y. Cue1p is an activator of Ubc7p E2 activity in vitro and in vivo. J. Biol. Chem., 2008, 283 (19), 12797-12810.
11. Li, W.; Tu, D.; Brunger, A.T.; Ye, Y. A ubiquitin ligase transfers preformed polyubiquitin chains from a conjugating enzyme to a substrate. Nature, 2007, 446 (7133), 333-337.
12. Ravid, T.; Hochstrasser, M. Autoregulation of an E2 enzyme by ubiquitin-chain assembly on its catalytic residue. Nat. Cell. Biol., 2007, 9 (4), 422-427.
13. Wang, M.; Pickart, C.M. Different HECT domain ubiquitin ligases employ distinct mechanisms of polyubiquitin chain synthesis. EMBO J., 2005, 24 (24), 4324-4333.
14. Vijay-Kumar, S.; Bugg, C.E.; Cook, W.J. Structure of ubiquitin refined at 1.8 A resolution. J. Mol. Biol., 1987, 194 (3), 531-544.
15. Behrends, C.; Harper, J.W. Constructing and decoding unconventional ubiquitin chains. Nat. Struct. Mol. Biol., 2011, 18 (5), 520-528.
16. Clague, M.J.; Urbe, S. Ubiquitin: same molecule, different degradation pathways. Cell, 2010, 143 (5), 682-685.
17. Rotin, D.; Kumar, S. Physiological functions of the HECT family of ubiquitin ligases. Nat. Rev. Mol. Cell. Biol., 2009, 10 (6), 398-409.
18. Sun, Y. Targeting E3 ubiquitin ligases for cancer therapy. Cancer Biol. Ther., 2003, 2 (6), 623-629.
19. Hatakeyama, S.; Nakayama, K.I. U-box proteins as a new family of ubiquitin ligases. Biochem. Biophys. Res. Commun., 2003, 302 (4), 635-645.
20. Aravind, L.; Iyer, L.M.; Koonin, E.V. Scores of RINGS but no PHDs in ubiquitin signaling. Cell Cycle, 2003, 2 (2), 123-126.
21. Huang, L.; Kinnucan, E.; Wang, G.; Beaudenon, S.; Howley, P.M.; Huibregtse, J.M.; Pavletich, N.P. Structure of an E6AP-UbcH7 complex: insights into ubiquitination by the E2-E3 enzyme cascade. Science, 1999, 286 (5443), 1321-1326.
22. Lorick, K.L.; Jensen, J.P.; Fang, S.; Ong, A.M.; Hatakeyama, S.; Weissman, A.M. RING fingers mediate ubiquitin-conjugating enzyme (E2)-dependent ubiquitination. Proc. Natl. Acad. Sci. USA., 1999, 96 (20), 11364-11369.
23. Metzger, M.B.; Pruneda, J.N.; Klevit, R.E.; Weissman, A.M. RING -type E3 ligases: master manipulators of E2 ubiquitin-conjugating enzymes and ubiquitination. Biochim. Biophys. Acta, 2014, 1843 (1), 47-60.
24. Ozkan, E.; Yu, H.; Deisenhofer, J. Mechanistic insight into the allosteric activation of a ubiquitin-conjugating enzyme by RINGtype ubiquitin ligases. Proc. Natl. Acad. Sci. USA., 2005, 102 (52), 18890-18895.
25. Liew, C.W.; Sun, H.; Hunter, T.; Day, C.L. RING domain dimerization is essential for RNF4 function. Biochem J., 2010, 431 (1), 23-29.
26. Hashizume, R.; Fukuda, M.; Maeda, I.; Nishikawa, H.; Oyake, D.; Yabuki, Y.; Ogata, H.; Ohta, T. The RING heterodimer BRCA1- BARD1 is a ubiquitin ligase inactivated by a breast cancer-derived mutation. J. Biol. Chem., 2001, 276 (18), 14537-14540.
27. Hua, Z.; Vierstra, R.D. The cullin-RING ubiquitin-protein ligases. Annu. Rev. Plant. Biol., 2011, 62, 299-334.
28. Petroski, M.D.; Deshaies, R.J. Function and regulation of cullin- RING ubiquitin ligases. Nat. Rev. Mol. Cell. Biol., 2005, 6 (1), 9-20.
29. Li, W; Bengtson, M.H.; Ulbrich, A.; Matsuda, A.; Reddy, V.A.; Orth, A.; Chanda, S.K.; Batalov, S.; Joazeiro, C.A. Genome-wide and functional annotation of human E3 ubiquitin ligases identifies MULAN, a mitochondrial E3 that regulates the organelle's dynamics and signaling. PLoS One, 2008, 3 (1), e1487.
30. Sharp, P.M.; Li, W.H. Ubiquitin genes as a paradigm of concerted evolution of tandem repeats. J. Mol. Evol., 1987, 25, 58-64.
31. Finley, D.; Bartel, B.; Varshavsky, A. The tails of ubiquitin precursors are ribosomal proteins whose fusion to ubiquitin facilitates ribosome biogenesis. Nature, 1989, 338 (6214), 394-401.
32. Catic, A.; Ploegh, H.L. Ubiquitin-conserved protein or selfish gene? Trends Biochem. Sci., 2005, 30, 600-604.
33. Zuin, A.; Isasa, M.; Crosas, B. Ubiquitin signaling systems: extreme conservation as a source of diversity. Cells, 2014, 3 (3), 690-701.
34. Komander, D.; Clague, M.J.; Urbe, S. Breaking the chains: structure and function of the deubiquitinases. Nat. Rev. Mol. Cell Biol., 2008, 10, 550-563.
35. Katz, E.J.; Isasa, M.; Crosas, B. A new map to understand deubiquitination. Biochem. Soc. Trans., 2010, 38 (1), 21-28.
36. Adams, J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell, 2004, 5 (5), 417-421.
37. Goldberg, A.L. Development of proteasome inhibitors as research tools and cancer drugs. J. Cell. Biol., 2012, 199 (4), 583-588.
38. Sippl, W.; Collura, V.; Colland, F. Ubiquitin-specific proteases as cancer drug targets. Future Oncolog., 2011, 7 (5), 619-632.
39. Lim, K.H.; Baek, K.H. Deubiquitinating enzymes as therapeutic targets in cancer. Curr. Pharm. Design, 2013. 19, 4039-4052.
40. Buckley, D.L.; Crews, C.M. Small-molecule control of intracellular protein levels through modulation of the ubiquitin proteasome system. Angew. Chem. Int. Ed. Engl., 2014, 53, 2312-2330.
41. Glickman, M.H.; Rubin, D.M.; Coux, O.; Wefes, I.; Pfeifer, G.; Cjeka, Z.; Baumeister, W.; Fried, V.A.; Finley, D. A subcomplex of the proteasome regulatory particle required for ubiquitinconjugate degradation and related to the COP9-signalosome and eIF3. Cell, 1998, 94, 615-623.
42. Lander, G.C.; Estrin, E.; Matyskiela, M.E.; Bashore, C.; Nogales, E.; Martin, A. Complete subunit architecture of the proteasome regulatory particle. Nature, 2012, 482, 186-191.
43. Yao, T.; Song, L.; Xu, W.; DeMartino, G.N.; Florens, L.; Swanson, S.K.; Washburn, M.P.; Conaway, R.C.; Conaway, J.W.; Cohen, R.E. Proteasome recruitment and activation of the Uch37 deubiquitinating enzyme by Adrm1. Nat. Cell Biol., 2006, 8 (9), 994-1002.
44. Leggett, D.S.; Hanna, J.; Borodovsky, A.; Crosas, B.; Schmidt, M.; Baker, R.T.; Walz, T., Ploegh, H.; Finley, D. Multiple associated proteins regulate proteasome structure and function. Mol. Cell, 2002, 10, 495-507.
45. Jiao, L.; Ouyang, S.; Shaw, N.; Song, G.; Feng, Y.; Niu, F.; Qiu, W.; Zhu, H.; Hung, L.W.; Zuo, X.; Eleonora Shtykova, V.; Zhu, P.; Dong, Y.H.; Xu, R.; Liu, Z.J. Mechanism of the Rpn13-induced activation of Uch37. Protein Cell, 2014 Apr 22. [Epub ahead of print].
46. Hanna, J.; Hathaway, N.A.; Tone, Y.; Crosas, B.; Elsasser, S.; Kirkpatrick, D.S.; Leggett, D.S.; Gygi, S.P.; King, R.W.; Finley, D. Deubiquitinating enzyme Ubp6 functions noncatalytically to delay proteasomal degradation. Cell, 2006, 127, 99-111.
47. Lee, B.H.; Lee, M.J.; Park, S.; Oh, D.C.; Elsasser, S; Chen, P.C.; Gartner, C.; Dimova, N.; Hanna, J.; Gygi, S.P.; Wilson, S.M., King, R.W.; Finley, D. Enhancement of proteasome activity by a small-molecule inhibitor of USP14. Nature, 2010, 467 (7312), 179-184.
48. D'Arcy, P.; Brnjic, S.; Olofsson, M.H.; Fryknas, M.; Lindsten, K.; De Cesare, M.; Perego, P. Sadeghi, B.; Hassan, M.; Larsson, R.; Linder, S. Inhibition of proteasome deubiquitinating activity as a new cancer therapy. Nat. Med., 2011, 17 (12), 1636-1640.
49. Wang, X.; Stafford, W.; Mazurkiewicz, M.; Fryknas, M.; Brjnic, S.; Zhang, X.; Gullbo, J.; Larsson, R.; Arner, E.S.; D'Arcy, P.; Linder, S.The 19S Deubiquitinase inhibitor b-AP15 is enriched in cells and elicits rapid commitment to cell death. Mol. Pharmacol., 2014, 85 (6), 932-945.
50. Brnjic, S.; Mazurkiewicz, M.; Fryknas, M.; Sun, C.; Zhang, X.; Larsson, R.; D'Arcy, P.; Linder, S. Induction of tumor cell apoptosis by a proteasome deubiquitinase inhibitor is associated with oxidative stress. Antioxid. Redox. Signal., 2013, Epub ahead of print.
51. Tian, Z.; D'Arcy, P.; Wang, X.; Ray, A.; Tai, Y.T.; Hu, Y. Carrasco, R.D.; Richardson, P.; Linder, S.; Chauhan, D.; Anderson, K.C. A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance. Blood, 2014, 123 (5), 706-716.
52. Liu, N.; Li, X.; Huang, H.; Zhao, C.; Liao, S.; Yang, C., Liu, S.; Song, W.; Lu, X.; Lan, X.; Chen, X.; Yi, S.; Xu, L.; Jiang, L.; Zhao, C.; Dong, X.; Zhou, P.; Li, S.; Wang, S.; Shi, X.; Dou, P.Q.; Wang X.; Liu, J. Clinically used antirheumatic agent auranofin is a proteasomal deubiquitinase inhibitor and inhibits tumor growth. Oncotarget. 2014 Jun 18. [Epub ahead of print].
53. Liu, N.; Liu, C.; Li, X.; Liao, S.; Song, W.; Yang, C.; Zhao, C.; Huang, H.; Guan, L.; Zhang, P.; Liu, S.; Hua, X.; Chen, X.; Zhou, P.; Lan, X.; Yi, S.; Wang, S.; Wang, X.; Dou, Q.P.; Liu, J. A novel proteasome inhibitor suppresses tumor growth via targeting both 19S proteasome deubiquitinases and 20S proteolytic peptidases. Sci. Rep., 2014, 4, 5240-5252.
54. Jung, H.; Kim, B.G.; Han, W.H.; Lee, J.H.; Cho, J.Y.; Park, W.S.; Maurice, M.M.; Han, J.K.; Lee, M.J.; Finley, D.; Jho, E.H. Deubiquitination of dishevelled by Usp14 is required for Wnt signaling. Oncogenesis, 2013, 2, e64.
55. Wu, N.; Liu, C.; Bai, C.; Han, Y.P.; Cho, W.C.; Li, Q. Overexpression of deubiquitinating enzyme USP14 in lung adenocarcinoma promotes proliferation through the accumulation of β-catenin. Int. J. Mol. Sci., 2013, 14 (6), 10749-10760.
56. Wu, N.; Zhang, C.; Bai, C.; Han, Y.P.; Li, Q.MiR-4782-3p inhibited non-small cell lung cancer growth via USP14. Cell Physiol. Biochem., 2014, 33 (2), 457-467.
57. Shinji, S.; Naito, Z.; Ishiwata, S.; Ishiwata, T.; Tanaka, N.; Furukawa, K.; Suzuki, H.; Seya, T.; Matsuda, A.; Katsuta, M.; Tajiri T. Ubiquitin-specific protease 14 expression in colorectal cancer is associated with liver and lymph node metastases. Oncol. Rep., 2006, 15 (3), 539-543.
58. Nag, D.K.; Finley, D. A small-molecule inhibitor of deubiquitinating enzyme USP14 inhibits Dengue virus replication. Virus Res., 2012, 165 (1), 103-106.
59. Anderson, C.; Crimmins, S.; Wilson, J.A.; Korbel, G.A.; Ploegh, H.L.; Wilson, S.M. Loss of Usp14 results in reduced levels of ubiquitin in ataxia mice. J. Neurochem., 2005, 95(3), 724-731.
60. Chen, P.C.; Qin, L.N.; Li, X.M.; Walters, B.J.; Wilson, J.A.; Mei, L.; Wilson, S.M. The proteasome-associated deubiquitinating enzyme Usp14 is essential for the maintenance of synaptic ubiquitin levels and the development of neuromuscular junctions. J. Neurosci., 2009, 29 (35), 10909-10919.
61. Bhattacharyya, B.J.; Wilson, S.M.; Jung, H.; Miller, R.J. Altered neurotransmitter release machinery in mice deficient for the deubiquitinating enzyme Usp14. Am. J. Physiol. Cell. Physiol., 2012, 302 (4), C698-708.
62. Jarome, T.J.; Kwapis, J.L.; Hallengren, J.J.; Wilson, S.M.; Helmstetter, F.J. The ubiquitin-specific protease 14 (USP14) is a critical regulator of long-term memory formation. Learn. Mem., 2013, 21 (1), 9-13.
63. Li, M.; Brooks, C.L.; Kon, N.; Gu, W. A dynamic role of HAUSP in the p53-Mdm2 pathway. Mol. Cell, 2004, 13 (6), 879-886.
64. Cummins, J.M.; Vogelstein, B. HAUSP is required for p53 destabilization. Cell Cycle, 2004, 3 (6), 689-692.
65. Sheng, Y.; Saridakis, V.; Sarkari, F.; Duan, S.; Wu, T.; Arrowsmith, C.H.; Frappier, L. Molecular recognition of p53 and MDM2 by USP7/HAUSP. Nat. Struct. Mol. Biol., 2006, 13 (3), 285-291.
66. Chauhan, D., Tian, Z.; Nicholson, B.; Kumar, K.G.; Zhou, B.; Carrasco, R.; McDermott, J.L.; Leach, C.A.; Fulcinniti, M., Kodrasov, M.P.; Weinstock, J.; Kingsbury, W.D.; Hideshima, T.; Shah, P.K.; Minvielle, S.; Altun, M.; Kessler, B.M.; Orlowski, R.; Richardson, P.; Munshi, N.; Anderson, K.C. A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. Cancer Cell, 2012, 22 (3), 345-358.
67. Colland, F. Ubiquitin and cancer: from molecular targets and mechanisms to the clinic. AACR Special Conference, 2006, 9, 179-181.
68. Colland, F.; Formstecher, E.; Jacq, X.; Reverdy, C.; Planquette, C.; Conrath, S.; Trouplin, V.; Bianchi, J.; Aushev, V.N.; Camonis, J.; Calabrese, A.; Borg-Capra, C.; Sippl, W.; Collura, V.; Boissy, G.; Rain, J.C.; Guedat, P.; Delansorne, R.; Daviet, L. Small-molecule inhibitor of USP7/HAUSP ubiquitin protease stabilizes and activates p53 in cells. Mol. Cancer Ther., 2009, 8 (8), 2286-2295.
69. Reverdy, C.; Conrath, S.; Lopez, R.; Planquette, C.; Atmanene, C.; Collura, V.; Harpon, J.; Battaglia, V.; Vivat, V.; Sippl, W.; Colland, F. Discovery of specific inhibitors of human USP7/HAUSP deubiquitinating enzyme. Chem. Biol., 2012, 19 (4), 467-477.
70. Fan, Y.H.; Cheng, J.; Vasudevan, S.A.; Dou, J.; Zhang, H.; Patel, R.H.; Ma, I.T.; Rojas, Y.; Zhao, Y.; Yu, Y.; Zhang, H.; Shohet, J.M.; Nuchtern, J.G.; Kim, E.S.; Yang, J. USP7 inhibitor P22077 inhibits neuroblastoma growth via inducing p53-mediated apoptosis. Cell Death Dis., 2013, 4, e867.
71. Yamaguchi, M.; Miyazaki, M.; Kodrasov, M.P.; Rotinsulu, H.; Losung, F.; Mangindaan, R.E.; de Voogd, N.J.; Yokosawa, H.; Nicholson, B.; Tsukamoto, S. Spongiacidin C, a pyrrole alkaloid from the marine sponge Stylissa massa, functions as a USP7 inhibitor. Bioorg. Med. Chem. Lett., 2013, 23 (13), 3884-3886.
72. Ching, W.; Koyuncu, E.; Singh, S.; Arbelo-Roman, C.; Hartl, B.; Kremmer, E.; Speiseder, T.; Meier, C.; Dobner, T. A ubiquitinspecific protease possesses a decisive role for adenovirus replication and oncogene-mediated transformation. PLoS Pathog., 2013, 9 (3), e1003273.
73. Nijman, S.M.; Huang, T.T.; Dirac, A.M.; Brummelkamp, T.R.; Kerkhoven, R.M.; D'Andrea, A.D.; Bernards, R. The deubiquitinating enzyme USP1 regulates the Fanconi anemia pathway. Mol. Cell 2005, 17, 331-339.
74. Cohn, M.A.; Kowal, P.; Yang, K.; et al. A UAF1-containing multisubunit protein complex regulates the Fanconi anemia pathway. Mol. Cell, 2007, 28, 786-797.
75. Lee, K.Y.; Yang, K.; Cohn, M.A.; Sikdar, N.; D'Andrea, A.D.; Myung, K. Human ELG1 regulates the level of ubiquitinated proliferating cell nuclear antigen (PCNA) through Its interactions with PCNA and USP1. J. Biol. Chem., 2010, 285, 10362-10369.
76. Kim, J.M.; Parmar, K.; Huang, M.; Weinstock, D.M.; Ruit, C.A.; Kutok, J.L.; D'Andrea, A.D. Inactivation of murine Usp1 results in genomic instability and a Fanconi anemia phenotype. Dev. Cell, 2009, 16 (2), 314-320.
77. Oestergaard, V.H; Langevin, F.; Kuiken, H.J.; Pace, P.; Niedzwiedz, W.; Simpson, L.J.; Ohzeki, M.; Takata, M.; Sale, J.E.; Patel, K.J. Deubiquitination of FANCD2 is required for DNA crosslink repair. Mol. Cell, 2007, 28 (5), 798-809.
78. Chen, J.; Dexheimer, T.S.; Ai, Y.; Liang, Q.; Villamil, M.A.; Inglese, J.; Maloney, D.J.; Jadhav, A.; Simeonov, A.; Zhuang, Z. Selective and cell-active inhibitors of the USP1/ UAF1 deubiquitinase complex reverse cisplatin resistance in non-small cell lung cancer cells. Chem. Biol., 2011, 18, 1390-1400.
79. Mistry, H.; Hsieh, G.; Buhrlage, S.J.; Huang, M.; Park, E.; Cuny, G.D.; Galinsky, I.; Stone, R.M. Gray, N.S.; D'Andrea, A.D.; Parmar, K. Small-molecule inhibitors of USP1 target ID1 degradation in leukemic cells. Mol. Cancer Ther., 2013, 12 (12), 2651-2662.
80. Liang, Q.; Dexheimer, T.S.; Zhang, P.; Rosenthal, A.S.; Villamil, M.A.; You, C.; Zhang, Q.; Chen, J.; Ott, C.A.; Sun, H.; Luci, D.K.; Yuan, B.; Simeonov, A.; Jadhav, A.; Xiao, H.; Wang, Y.; Maloney, D.J. Zhuang, Z. A selective USP1-UAF1 inhibitor links deubiquitination to DNA damage responses. Nat. Chem. Biol., 2014, 10 (4), 298-304.
81. Mizuno, E.; Kobayashi, K.; Yamamoto, A.; Kitamura, N; Komada, M. A deubiquitinating enzyme UBPY regulates the level of protein ubiquitination on endosomes. Traffic, 2006, 7 (8), 1017-10131.
82. Row, P.E.; Prior, I.A.; McCullough, J.; Clague, M.J.; Urbe, S. The ubiquitin isopeptidase UBPY regulates endosomal ubiquitin dynamics and is essential for receptor down-regulation. J. Biol. Chem., 2006, 281 (18), 12618-12624.
83. Alwan, H.A.; van Leeuwen, J.E. UBPY-mediated epidermal growth factor receptor (EGFR) de-ubiquitination promotes EGFR degradation. J. Biol. Chem., 2007, 282 (3), 1658-1669.
84. Ali, N.; Zhang, L.; Taylor, S.; Mironov, A.; Urbe, S.; Woodman, P. Recruitment of UBPY and ESCRT exchange drive HD-PTPdependent sorting of EGFR to the MVB. Curr. Biol., 2013, 23 (6), 453-461.
85. Byun, S.; Lee, S.Y.; Lee, J.; Jeong, C.H.; Farrand, L.; Lim, S.; Reddy, K.; Kim, J.Y.; Lee, M.H.; Lee, H.J.; Bode, A.M.; Won Lee, K.; Dong, Z. USP8 is a novel target for overcoming gefitinib resistance in lung cancer. Clin. Cancer Res., 2013, 19 (14), 3894-3904.
86. Colombo, M.; Vallese, S.; Peretto, I.; Jacq, X.; Rain, J.C.; Colland, F.; Guedat, P. Synthesis and biological evaluation of 9-oxo-9Hindeno[ 1,2-b]pyrazine-2,3-dicarbonitrile analogues as potential inhibitors of deubiquitinating enzymes. Chem. Med. Chem., 2010, 5 (4), 552-558.
87. Ferrajoli, A.; Faderl, S.; Van, Q.; Koch, P.; Harris, D.; Liu, Z.; Hazan-Halevy, I.; Wang, Y.; Kantarjian, H.M.; Priebe, W.; Estrov, Z. WP1066 disrupts Janus kinase-2 and induces caspase-dependent apoptosis in acute myelogenous leukemia cells. Cancer Res., 2007, 67, 11291-11299.
88. Verstovsek, S.; Manshouri, T.; Quintas-Cardama, A.; Harris, D.; Cortes, J.; Giles, F.J.; Kantarjian, H.; Priebe, W.; Estrov, Z. WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cell s carrying the JAK2 V617F mutation. Clin. Cancer Res., 2008, 14, 788-796.
89. Bartholomeusz, G.A.; Talpaz, M.; Kapuria, V.; Kong, L.Y.; Wang, S.; Estrov, Z.; Priebe, W.; Wu, J.; Donato, N.J. Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells. Blood, 2007, 109 (8), 3470-3478.
90. Bartholomeusz, G.; Talpaz, M.; Bornmann, W.; Kong, L.Y.; Donato, N.J. Degrasyn activates proteasomal-dependent degradation of c-Myc. Cancer Res., 2007, 67 (8), 3912-3918.
91. Pham, L.V.; Tamayo, A.T.; Li, C.; Bornmann, W.; Priebe, W.; Ford, R.J. Degrasyn potentiates the antitumor effects of bortezomib in mantle cell lymphoma cells in vitro and in vivo: therapeutic implications. Mol. Cancer Ther., 2010, 9 (7), 2026-2036.
92. Kapuria, V.; Peterson, L.F.; Fang, D.; Bornmann, W.G.; Talpaz, M.; Donato, N.J. Deubiquitinase inhibition by small-molecule WP1130 triggers aggresome formation and tumor cell apoptosis. Cancer Res., 2010, 70 (22), 9265-9276.
93. Sun, H.; Kapuria, V.; Peterson, L.F.; Fang, D.; Bornmann, W.G.; Bartholomeusz, G.; Talpaz, M.; Donato, N.J. Bcr-Abl ubiquitination and Usp9x inhibition block kinase signaling and promote CML cell apoptosis. Blood, 2011, 117 (11), 3151-3162.
94. Noma, T.; Kanai, Y.; Kanai-Azuma, M.; Ishii, M. Fujisawa, M.; Kurohmaru, M.; Kawakami, H.; Wood, S.A.; Hayashi, Y. Stageand sex-dependent expressions of Usp9x, an X-linked mouse ortholog of Drosophila Fat facets, during gonadal development and oogenesis in mice. Mech. Dev., 2002, 119, Suppl 1, 91-95.
95. Sato, T.; Kanai, Y.; Noma, T.; Kanai-Azuma, M.; Taya, S.; Matsui, T.; Ishii, M.; Kawakami, H.; Kurohmaru, M., Kaibuchi, K., Wood, S.A.; Hayashi, Y.A. Close correlation in the expression patterns of Af-6 and Usp9x in Sertoli and granulosa cells of mouse testis and ovary. Reproduction, 2004, 128 (5), 583-594.
96. Xu, J.; Taya, S.; Kaibuchi, K.; Arnold, A.P. Spatially and temporally specific expression in mouse hippocampus of Usp9x, a ubiquitin-specific protease involved in synaptic development. J. Neurosci. Res., 2005, 80 (1), 47-55.
97. Dupont, S.; Mamidi, A.; Cordenonsi, M.; Montagner, M.; Zacchigna, L.; Adorno, M.; Martello, G.; Stinchfield, M.J.; Soligo, S.; Morsut, L.; Inui, M.; Moro, S.; Modena, N.; Argenton, F.; Newfeld, S.J.; Piccolo, S. FAM/USP9x, a deubiquitinating enzyme essential for TGFbeta signaling, controls Smad4 monoubiquitination. Cell, 2009, 136 (1), 123-135.
98. Peng, J.; Hu, Q.; Liu, W.; He, X.; Cui, L.; Chen, X.; Yang, M.; Liu, H.; Wei, W.; Liu, S.; Wang, H.USP9X expression correlates with tumor progression and poor prognosis in esophageal squamous cell carcinoma. Diagn. Pathol., 2013, 8 (1), 177.
99. Schwickart, M.; Huang, X.; Lill, J.R.; Liu, J.; Ferrando, R.; French, D.M.; Maecker, H.; O'Rourke, K.; Bazan, F.; Eastham-Anderson, J.; Yue, P.; Dornan, D.; Huang, D.C.; Dixit, V.M. Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. Nature, 2010, 463 (7277), 103-107.
100. Theard, D.; Labarrade, F.; Partisani, M.; Milanini, J.; Sakagami, H.; Fon, E.A.; Wood, S.A.; Franco, M.; Luton, F. USP9x-mediated deubiquitination of EFA6 regulates de novo tight junction assembly. EMBO J., 2010, 29 (9), 1499-1509.
101. Wang, S.; Kollipara, R.K.; Srivastava, N.; Li, R.; Ravindranathan, P. Hernandez, E.; Freeman, E.; Humphries, C.G.; Kapur, P.; Lotan, Y.; Fazli, L.; Gleave, M.E.; Plymate, S.R.; Raj, G.V.; Hsieh, J.T.; Kittler, R. Ablation of the oncogenic transcription factor ERG by deubiquitinase inhibition in prostate cancer. Proc. Natl. Acad. Sci. USA, 2014, 111 (11), 4251-4256.
102. Xie, C.; Koshino, H.; Esumi, Y.; Takahashi, S.; Yoshikawa, K.; et al. Vialinin A, a novel 2,2-diphenyl-1-picrylhydrazyl (DPPH) radical scavenger from an edible mushroom in China. Biosci. Biotechnol. Biochem., 2005, 69, 2326-2332.
103. Onose, J.; Xie, C.; Ye, Y.Q.; Sugaya, K.; Takahashi, S.; Koshino, H.; Yasunaga, K.; Abe, N.; Yoshikawa, K. Vialinin A, a novel potent inhibitor of TNF-a production from RBL-2H3 cells. Biol. Pharm. Bull., 2008, 31, 831-833.
104. Onose, J.; Yoshioka, Y.; Ye, Y.Q.; Sugaya, K.; Yajima, A.; Taniquchi, K.; Okada, K.; Yajima, S.; Takahashi, S.; Koshino, H.; Abe, N. Inhibitory effects of vialinin A and its analog on tumor necrosis factor-a release and production from RBL-2H3 cells. Cell Immunol., 2012, 279, 140-144.
105. Okada, K.; Ye, Y.Q.; Taniguchi, K.; Yoshida, A.; Akiyama, T.; Yoshioka, Y.; Onose, J.; Koshino, H.; Takahashi, S.; Yajima, A.; Abe, N.; Yajima, S. Vialinin A is a ubiquitin-specific peptidase inhibitor. Bioorg. Med. Chem. Lett., 2013, 23 (15), 4328-4331.
106. Izaguirre, D.I.; Zhu, W.; Hai, T.; Cheung, H.C.; Krahe, R.; Cote G.J. PTBP1-dependent regulation of USP5 alternative RNA splicing plays a role in glioblastoma tumorigenesis. Mol. Carcinog., 2012, 51 (11), 895-906.
107. Kapuria, V.; Peterson, L.F.; Fang, D.; Bornmann, W.G.; Talpaz, M.; Donato, N.J. Deubiquitinase inhibition by small-molecule WP1130 triggers aggresome formation and tumor cell apoptosis. Cancer Res., 2010, 70 (22), 9265-9276.
108. Issaenko, O.A.; Amerik, A.Y. Chalcone-based small-molecule inhibitors attenuate malignant phenotype via targeting deubiquitinating enzymes. Cell Cycle, 2012, 11 (9), 1804-1817.
109. Norikura, T.; Fujiwara, K.; Narita, T.; Yamaguchi, S.; Morinaga, Y.; Iwai, K.; Matsue, H. Anticancer activities of thelephantin O and vialinin A isolated from Thelephora aurantiotincta. J. Agric. Food. Chem., 2011, 59 (13), 6974-6979.
110. Coughlin, K.; Anchoori, R.; Iizuka, Y.; Meints, J.; MacNeill, L.; Vogel, R.I.; Orlowski, R.Z.; Lee, M.K.; Roden, R.B.; Bazzaro, M. Small-molecule RA-9 inhibits proteasome-associated dubs and ovarian cancer in vitro and in vivo via exacerbating unfolded protein responses. Clin. Cancer Res., 2014, 20 (12), 3174-3186.
111. Liu, J.; Xia, H.; Kim, M.; Xu L.; Li, Y.; Zhang, L.; Cai, Y.; Norberg, H.V.; Zhang, T.; Furuya, T.; Jin, M.; Zhu, Z.; Wang H.; Yu J.; Li, Y.; Hao, Y.; Choi, A.; Ke, H.; Ma, D.; Yuan, J. Beclin1 controls the levels of p53 by regulating the deubiquitination activity of USP10 and USP13. Cell, 2011, 147 (1), 223-234.
112. Yuan, J.; Luo, K.; Zhang, L.; Cheville, J.C.; Lou, Z. USP10 regulates p53 localization and stability by deubiquitinating p53. Cell, 2010, 140 (3), 384-396.
113. Schoenfeld, A.R.; Apgar, S.; Dolios, G.; Wang, R.; Aaronson, S.A.BRCA2 is ubiquitinated in vivo and interacts with USP11, a deubiquitinating enzyme that exhibits prosurvival function in the cellular response to DNA damage. Mol Cell Biol., 2004, 24 (17), 7444-7455.
114. Burkhart, R.A.; Peng, Y.; Norris, Z.A.; Tholey, R.M.; Talbott, V.A.; Liang, Q.; Ai, Y.; Miller, K.; Lal, S.; Cozzitorto, J.A.; Witkiewicz, A.K.; Yeo, C.J.; Gehrmann M.; Napper, A.; Winter, J.M.; Sawicki, J.A.; Zhuang, Z.; Brody, J.R. Mitoxantrone targets human ubiquitin-specific peptidase 11 (USP11) and is a potent inhibitor of pancreatic cancer cell survival. Mol. Cancer Res., 2013, 11 (8), 901-911.
115. Lio, P.; Goldman, N. Phylogenomics and bioinformatics of SARSCoV. Trends Microbiol., 2004, 12 (3), 106-111.
116. Ratia, K.; Pegan, S.; Takayama, J.; Sleeman, K.; Coughlin, M.; Baliji, S.; Chaudhuri, R.; Fu, W.; Prabhakar, B.S.; Johnson, M.E.; Baker, S.C.; Ghosh, A.K.; Mesecar, A.D. A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication. Proc. Natl. Acad. Sci. USA, 2008, 105 (42), 16119-16124
117. Chou, C.Y; Chien, C.H.; Han, Y.S.; Prebanda, M.T.; Hsieh, H.P.; Turk, B.; Chang. G.G.; Chen, X. Thiopurine analogues inhibit papain-like protease of severe acute respiratory syndrome coronavirus. Biochem. Pharmacol., 2008, 75 (8), 1601-1609.
118. Sowa, M.E.; Bennett, E.J.; Gygi, S.P.; Harper, J.W. Defining the human deubiquitinating enzyme interaction landscape. Cell, 2009, 138, 389-403.